Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCHW) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Envoy Medical (COCHW) over the last 4 years, with Q2 2025 value amounting to -$1000.0.

  • Envoy Medical's Cash from Investing Activities rose 9987.34% to -$1000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $527000.0, marking a year-over-year increase of 13433.22%. This contributed to the annual value of -$980000.0 for FY2024, which is 54052.29% down from last year.
  • Latest data reveals that Envoy Medical reported Cash from Investing Activities of -$1000.0 as of Q2 2025, which was up 9987.34% from -$6000.0 recorded in Q1 2025.
  • In the past 5 years, Envoy Medical's Cash from Investing Activities registered a high of $534000.0 during Q4 2024, and its lowest value of -$790000.0 during Q2 2024.
  • Moreover, its 4-year median value for Cash from Investing Activities was -$41000.0 (2022), whereas its average is -$107363.6.
  • The largest annual percentage gain for Envoy Medical's Cash from Investing Activities in the last 5 years was 264285.71% (2024), contrasted with its biggest fall of 708181.82% (2024).
  • Over the past 4 years, Envoy Medical's Cash from Investing Activities (Quarter) stood at -$41000.0 in 2022, then soared by 48.78% to -$21000.0 in 2023, then skyrocketed by 2642.86% to $534000.0 in 2024, then plummeted by 100.19% to -$1000.0 in 2025.
  • Its Cash from Investing Activities was -$1000.0 in Q2 2025, compared to -$6000.0 in Q1 2025 and $534000.0 in Q4 2024.